Compare

GSK/$GSK

GSK stock rises after Health Canada approved Hibsago, its hepatitis B treatment and the first finite therapy in Canada indicated to achieve a functional cure.
12 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX

About GSK

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Ticker
$GSK
Sector
Health
Primary listing
NYSE
Employees
66,841
Headquarters
London, United Kingdom
Website
www.gsk.com

GSK Metrics

BasicAdvanced
$102B
35.54
$1.44
0.28
$1.79
3.46%

What the Analysts think about GSK

Analyst ratings (Buy, Hold, Sell) for GSK stock.
Analyst projections of the future price of GSK stock.

Bulls say / Bears say

Specialty medicines are driving growth: Q3 sales rose 15%, led by HIV, respiratory and oncology, helping lift group revenue 5% at constant exchange rates. GSK also beat quarterly earnings expectations and kept its 2026 outlook. (GSK, Reuters)
Recent approvals and pipeline progress could broaden GSK’s future growth beyond established products: Hibsago and Jemperli gained US approvals, and the company is progressing towards 22 Phase III trial starts in 2026. (GSK)
GSK’s plan to save £1.9bn a year by 2029 is intended to fund drug development and support margins through the dolutegravir patent expiry period. Management expects margins to be stable or improve across 2028–30. (GSK)
Vaccines remain a weak spot: Q3 sales fell 2%, with Shingrix down 5% and Arexvy down 24%, and the division missed market expectations. Persistent weakness would weigh on a sizeable part of the business. (Reuters)
Dolutegravir-based HIV medicines face patent expiries between 2028 and 2030, putting an important source of sales at risk. GSK needs its newer long-acting treatments to grow enough to offset potential generic competition. (Reuters)
GSK’s long-term growth target may be hard to reach: analyst forecasts put 2031 sales at £36.64bn, below the company’s goal of more than £40bn. Exdensur also missed expectations, while R&D spending is expected to grow faster than sales. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.

GSK Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

GSK Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

GSK News

AllArticlesVideos

What GSK (GSK) Said on Its Q3 Earnings Call

MarketBeat1 week ago

GSK's Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat

Benzinga1 week ago

GSK Sales Get Boost From Specialty Medicines

WSJ1 week ago

Funds containing GSK

AllGBPEURUSD
Funds
Fund name
Fund size
$GSK weighting
Vanguard FTSE 100£VUKE
£4.7B2.87%
Vanguard FTSE 100£VUKG
£1.9B2.87%
Vanguard ESG Developed Europe All Cap£V3EA
€125M0.91%
Vanguard ESG Developed Europe All Cap£V3EL
€35M0.91%
Vanguard FTSE Developed Europe$VEUD
€4.8B0.68%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.